Vaccines Against Virally Induced Cancers (Novartis Foundation Symposia)

An interdisciplinary and multinational group of specialists present contributions describing the current status of vaccines against virally induced tumors and discuss the means by which they can be improved. VACCINES AGAINST VIRALLY INDUCED CANCERS 5 Contents 7 Participants 10 Introduction 13 Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response 16 The host response to lesions induced by human papillomavirus 33 General discussion I 57 Human T cell lymphotropic virus: necessity for and feasibility of a vaccine 59 Vaccination against cutaneous and mucosal papillomavirus in cattle 73 Strategies for studying mouse and human immune responses to human papillomavirus type 16 90 Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and su bdominant peptides 109 Hepatitis B virus infection, the immune response and hepatocellular carcinoma 125 The role of superantigens in the immunobiology of retroviruses 144 General discussion II 156 Assembly and transport of class I MHC-peptide complexes 162 Induction and regulation of CD4+ T cell subsets 182 Propagation of mouse and human T cells with defined antigen specificity and function 191 Immunity to the HER-2/neu oncogenic protein 210 Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy 224 Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses 241 Evasion of host immune responses by tumours and viruses 257 Final dscussion 273 Index of contributors 283 Subject index 285 0471950262,9780471950264 Wiley Exploring the development of vaccines against virally-associated cancer, this volume describes the current status of vaccines and discusses plans for their improvement. It also considers other means of stimulating the host immune system to combat virally-induced cancers.